Skip to search formSkip to main contentSkip to account menu
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
TLDR
Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
View on PubMed
A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.
TLDR
A tissue inhibitor of metalloproteinases that also inhibits collagenases was found to be a potent inhibitor of fibroblast growth factor-induced angiogenesis, allowing the ready quantitative assessment of angiogenic and anti-angiogenic factors.
View on PubMed
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
TLDR
Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week, demonstrating that HIF-1 is a critical target of digoxin for cancer therapy.
View on Publisher
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
View on Elsevier
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.
TLDR
Treatment of the VHL-deficient human renal cell carcinoma cell line UMRC2 with the hydroxamic HDAC inhibitor LAQ824 resulted in a dose-dependent inhibition of HIF-1 alpha protein via a V HL-independent mechanism and reduction of Hif-1alpha transcriptional activity, suggesting that class II HDACs are associated with HIF's alpha stability.
View on PubMed
Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1.
View on PubMed
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
TLDR
The results demonstrate that entinostat enhances the antitumor effect of PD-1 targeting through functional inhibition of MDSCs and a transition away from an immune-suppressive tumor microenvironment.
View on Publisher
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
TLDR
On the basis of plasma exposures and safety data, enzastaurin 525 mg once daily is the recommended phase II dose and evidence of early activity was seen with significant stable disease.
View on PubMed
Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589
TLDR
Evidence is provided that LBH589 induces a wide range of effects on endothelial cells that lead to inhibition of tumor angiogenesis, which support the role of HDAC inhibitors as a therapeutic strategy to target both the tumor and endothelial compartment and warrant the clinical development of these agents in combination with angiogenic inhibitors.
View on Publisher
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
TLDR
It is reported that sunit inib inhibits tumor cell proliferation at clinically relevant concentrations and found lysosomal sequestration to be a novel mechanism of sunitinib resistance.
View on Publisher
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License